Suchergebnisse - "Tay, Jason"

PubPharm (6)

1

Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens : Experience From the Amyloidosis Program of Calgary

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Lewis, E. | McCulloch, S. | Mahe, E. | +5

2

Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Nie, C. | Lee, H. | Tay, J. | +5

3

The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease : A single-center experience

enthalten in: European journal of haematology | 2021

von Lee, H. | Tay, J. | Duggan, P. | +4

4

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis : Impact of Response on Survival Outcomes

enthalten in: Clinical lymphoma, myeloma & leukemia | 2020

von Diaz-Pallares, C. | Lee, H. | Luider, J. | +6

5

Bortezomib-containing regimens (BCR) for the treatment of non-transplant eligible multiple myeloma

enthalten in: Annals of hematology | 2017

von Jimenez-Zepeda, V. | Duggan, P. | Neri, P. | +2

6

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR) : a randomised, phase 3, open-label, multicentre study

enthalten in: The Lancet. Oncology | 2016

von Dimopoulos, M. | Moreau, P. | Palumbo, A. | +129

CommentIn: Lancet Oncol. 2016 Jan;17(1):2-3. - PMID 26671819

1
[1]